|
US5986054A
(en)
|
1995-04-28 |
1999-11-16 |
The Hospital For Sick Children, Hsc Research And Development Limited Partnership |
Genetic sequences and proteins related to alzheimer's disease
|
|
JP4073955B2
(ja)
*
|
1995-07-07 |
2008-04-09 |
ダーウィン モレキュラー コーポレイション |
アルツハイマー病に関連する第１染色体の遺伝子および遺伝子産物
|
|
AU6343196A
(en)
*
|
1995-07-18 |
1997-02-18 |
University Of South Florida |
Mutant s182 genes
|
|
EP0846172A2
(en)
*
|
1995-08-16 |
1998-06-10 |
The President And Fellows Of Harvard College |
Assay for identifying genes causing chromosome non-disjunction
|
|
US6248555B1
(en)
|
1995-08-31 |
2001-06-19 |
The General Hospital Corporation |
Genetic alterations related to familial alzheimer's disease
|
|
WO1997011956A1
(en)
|
1995-09-27 |
1997-04-03 |
The Trustees Of Columbia University In The City Of New York |
IDENTIFICATION OF sel-12 AND USES THEREOF
|
|
ZA968898B
(en)
*
|
1995-10-25 |
1998-03-30 |
Washington University Of Medic |
Method for elucidation and detection of polymorphisms, splice variants and proximal coding mutations using intronic sequences of the mutations Alzheimer's S182 gene.
|
|
JPH10327897A
(ja)
*
|
1996-01-19 |
1998-12-15 |
Washington Univ |
プレセニリン−１遺伝子の配列を用いる疾患の診断および予後診断
|
|
JP2000506375A
(ja)
*
|
1996-01-26 |
2000-05-30 |
エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ |
アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
|
|
AU2541497A
(en)
*
|
1996-04-04 |
1997-10-29 |
Institute Of Genomic Research, The |
Variant presenilin-2 genes
|
|
WO1997046678A1
(en)
*
|
1996-06-06 |
1997-12-11 |
Bayer Corporation |
Nucleic acids and polypeptides related to presenilin
|
|
EP0811695A3
(en)
*
|
1996-06-06 |
1998-07-29 |
Washington University |
Mutant S182(PS-1) genes
|
|
EP0814157A3
(en)
*
|
1996-06-18 |
1998-01-07 |
Smithkline Beecham Corporation |
Diagnostic marker for variants of presenilin genes associated with Alzheimers Disease and Familial Adult Onset Alzheimers Disease
|
|
CA2259618A1
(en)
*
|
1996-07-05 |
1998-01-15 |
The Governing Council Of The University Of Toronto |
Genetic sequences and proteins related to alzheimer's disease, and uses therefor
|
|
WO1998025142A1
(en)
|
1996-12-02 |
1998-06-11 |
The Brigham And Women's Hospital, Inc. |
Alarm related peptides and nucleic acids and diagnosis using them
|
|
US6121045A
(en)
*
|
1997-04-04 |
2000-09-19 |
Millennium Biotherapeutics, Inc. |
Human Delta3 nucleic acid molecules
|
|
US6376239B1
(en)
*
|
1997-04-04 |
2002-04-23 |
Elegene Gmbh |
DNA molecules comprising a promoter capable of conferring expression of a heterologous DNA sequence
|
|
EP0977776A2
(en)
*
|
1997-04-24 |
2000-02-09 |
The General Hospital Corporation |
A PURIFIED 20 kDa PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2
|
|
JP2001514528A
(ja)
*
|
1997-05-14 |
2001-09-11 |
メルク エンド カンパニー インコーポレーテッド |
天然プレセニリン１ヌルバックグラウンド上で非天然野生型および家族性アルツハイマー病突然変異プレセニリン１タンパク質を発現するトランスジェニック動物
|
|
ES2128265B1
(es)
*
|
1997-06-04 |
2000-03-01 |
Euroespes S A |
Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
|
|
US7923015B2
(en)
*
|
1997-08-14 |
2011-04-12 |
Institut Pasteur |
Methods for direct visualization of active synapses
|
|
ES2281135T3
(es)
*
|
1997-08-14 |
2007-09-16 |
Institut Pasteur |
Proteinas hibridas de un toxoide tetanico que migran de forma retrograda y transinaptica al snc.
|
|
US20100081197A1
(en)
*
|
1997-08-14 |
2010-04-01 |
Sylvie Roux |
In vivo modulation of neuronal transport
|
|
US7923216B2
(en)
*
|
1997-08-14 |
2011-04-12 |
Institut Pasteur |
In vivo modulation of neuronal transport
|
|
US6284944B1
(en)
|
1997-08-29 |
2001-09-04 |
Cephalon, Inc, |
Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
|
|
US6255473B1
(en)
*
|
1997-08-29 |
2001-07-03 |
Duke University |
Presenilin-1 gene promoter
|
|
FR2768346B1
(fr)
*
|
1997-09-15 |
2002-04-19 |
Fond Jean Dausset Ceph |
Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic
|
|
FR2770217B1
(fr)
*
|
1997-10-24 |
2001-12-07 |
Rhone Poulenc Rorer Sa |
Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
|
|
CN100429230C
(zh)
*
|
1997-10-24 |
2008-10-29 |
阿文蒂斯药物股份有限公司 |
能抑制早老素和β-淀粉样肽或其前体间相互作用的肽
|
|
CA2317809A1
(en)
*
|
1998-01-08 |
1999-07-15 |
Daiichi Pharmaceutical Co., Ltd. |
Gene mutant animals
|
|
AU1957299A
(en)
*
|
1998-01-09 |
1999-07-26 |
Governing Council Of The University Of Toronto, The |
Presenilin protein interactions
|
|
EP1849477A1
(en)
*
|
1998-02-25 |
2007-10-31 |
THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY |
Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by ADP-ribosylating exotoxin
|
|
AU3849499A
(en)
*
|
1998-05-21 |
1999-12-06 |
Tanabe Seiyaku Co., Ltd. |
Method for examining central nervous system diseases and method for screening remedies
|
|
AR020329A1
(es)
*
|
1998-07-09 |
2002-05-08 |
Boehringer Ingelheim Pharma |
UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C
|
|
CA2333467A1
(en)
*
|
1998-07-16 |
2000-01-27 |
Incyte Pharmaceuticals, Inc. |
Human presenilin-associated protein
|
|
US6797480B1
(en)
|
1998-10-05 |
2004-09-28 |
University Of Connecticut Health Center |
Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
|
|
US6723557B1
(en)
|
1999-01-06 |
2004-04-20 |
California Institute Of Technology |
Caenorhabditis elegans LOV-1 gene
|
|
US6783982B1
(en)
|
1999-02-12 |
2004-08-31 |
The Governing Council Of The University Of Toronto |
Proteins related to neuronal regeneration and uses thereof
|
|
US6812337B1
(en)
|
1999-04-01 |
2004-11-02 |
The Governing Council Of The University Of Toronto |
Presenilin associated membrane protein and uses thereof
|
|
US6890726B1
(en)
|
1999-04-06 |
2005-05-10 |
Oklahoma Medical Research Foundation |
Method for selecting recombinase variants with altered specificity
|
|
US6374130B1
(en)
*
|
1999-04-06 |
2002-04-16 |
Eric M. Reiman |
Methods for tracking the progression of Alzheimer's disease identifying treatment using transgenic mice
|
|
US20030131364A1
(en)
*
|
1999-04-27 |
2003-07-10 |
Karen Duff |
Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
|
|
AU6265600A
(en)
*
|
1999-06-22 |
2001-01-09 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Method for detection of early-onset alzheimer's disease
|
|
CA2374610A1
(en)
*
|
1999-06-28 |
2001-01-04 |
Jordan J. N. Tang |
Catalytically active recombinant memapsin and methods of use thereof
|
|
US20020049303A1
(en)
*
|
1999-06-28 |
2002-04-25 |
Tang Jordan J. N. |
Catalytically active recombinant memapsin and methods of use thereof
|
|
FR2798821B1
(fr)
*
|
1999-09-27 |
2001-10-26 |
Aventis Pharma Sa |
Animal transgenique exprimant une forme multi-mutee de la preseniline 1
|
|
AU2001227960A1
(en)
*
|
2000-01-21 |
2001-07-31 |
University Of Connecticut Health Center |
Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
|
|
CA2405332A1
(en)
|
2000-04-03 |
2001-10-11 |
Bristol-Myers Squibb Company |
Fluorescence assay for gamma-secretase activity and inhibitors
|
|
WO2001092576A1
(en)
*
|
2000-05-26 |
2001-12-06 |
Duke University |
Methods of screening for parkinson's disease
|
|
AU2001268328A1
(en)
*
|
2000-06-12 |
2001-12-24 |
University Of Maryland Biotechnology Institute |
Method of controlling the binding of calmyrin to presenilin
|
|
US7371920B2
(en)
*
|
2000-06-20 |
2008-05-13 |
The Governing Council Of The University Of Toronto |
Transgenic mouse model of neurodegenerative disorders
|
|
WO2002002000A2
(en)
*
|
2000-06-30 |
2002-01-10 |
Duke University |
Methods of screening for alzheimer's disease
|
|
DE10032709A1
(de)
*
|
2000-07-07 |
2002-01-24 |
Boehringer Ingelheim Pharma |
Aspartyl-Protease
|
|
WO2002005634A2
(en)
|
2000-07-13 |
2002-01-24 |
University Of South Florida |
Transgenic animal and methods
|
|
JP2002142765A
(ja)
*
|
2000-07-14 |
2002-05-21 |
Tosoh Corp |
新規ゲノム解析法
|
|
CA2418087A1
(en)
*
|
2000-08-16 |
2002-02-21 |
Markus Fritzsche |
Use of microbial dna sequences for the identification of human diseases
|
|
AU2001287448A1
(en)
*
|
2000-09-01 |
2002-03-13 |
The Governing Council Of The University Of Toronto |
Proteins related to schizophrenia and uses thereof
|
|
US6900367B2
(en)
*
|
2000-09-29 |
2005-05-31 |
Novartis |
Transgenic Drosophila melanogaster expressing a β42 in the eye
|
|
US6495335B2
(en)
*
|
2000-12-07 |
2002-12-17 |
Mario Chojkier |
Compositions and methods for diagnosing alzheimer's disease
|
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
|
US6815175B2
(en)
|
2001-03-16 |
2004-11-09 |
Cornell Research Foundation, Inc. |
Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
|
|
US20030073608A1
(en)
*
|
2001-04-10 |
2003-04-17 |
Woolf Nancy J. |
Process for treating disease
|
|
GB2375771A
(en)
*
|
2001-05-24 |
2002-11-27 |
Univ Leeds |
Decellularisation of tissue implant material
|
|
JP2003012548A
(ja)
*
|
2001-06-27 |
2003-01-15 |
Japan Science & Technology Corp |
医薬組成物
|
|
EP2354156A3
(en)
|
2001-08-14 |
2011-11-16 |
Sentigen Biosciences, Inc. |
Nucleic acids and proteins of insect OR83B odorant receptor genes and uses thereof
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
JP4547152B2
(ja)
*
|
2001-10-23 |
2010-09-22 |
オクラホマ メディカル リサーチ ファウンデーション |
β−セクレターゼ阻害剤および使用方法
|
|
EP1456668B1
(en)
*
|
2001-12-05 |
2007-05-02 |
Sense Proteomic Limited |
Protein arrays for allelic variants and uses thereof
|
|
US7479579B2
(en)
*
|
2001-12-20 |
2009-01-20 |
The Regents Of The University Of California |
Triple transgenic mouse model of Alzheimer's disease
|
|
US20040014109A1
(en)
*
|
2002-05-23 |
2004-01-22 |
Pericak-Vance Margaret A. |
Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
|
|
EP1520172A1
(en)
*
|
2002-07-05 |
2005-04-06 |
EVOTEC Neurosciences GmbH |
Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
|
|
AU2003251962A1
(en)
*
|
2002-07-08 |
2004-01-23 |
Duke University |
Screening for alzheimer's disease
|
|
US20040076606A1
(en)
*
|
2002-09-14 |
2004-04-22 |
Ming-Shi Chang |
Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding
|
|
US7022481B2
(en)
|
2002-12-19 |
2006-04-04 |
Rosetta Inpharmatics Llc |
Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
|
|
US20060246437A1
(en)
*
|
2003-07-11 |
2006-11-02 |
Pericak-Vance Margaret A |
Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
|
|
US20060068428A1
(en)
*
|
2003-11-03 |
2006-03-30 |
Duke University |
Identification of genetic markers associated with parkinson disease
|
|
US20050191652A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Vance Jeffery M. |
Identification of genetic forms of a gene that leads to high risk for parkinson disease
|
|
WO2005074994A1
(en)
*
|
2004-01-30 |
2005-08-18 |
Xenoport, Inc. |
Oat3 transporter expressed in blood brain barrier cells
|
|
US20050170393A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Xenoport, Inc. |
OATPB transporters expressed in blood brain barrier cells
|
|
SE0400707D0
(sv)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
|
US7790390B2
(en)
*
|
2004-10-27 |
2010-09-07 |
Duke University |
Methods for identifying an individual at increased risk of developing coronary artery disease
|
|
US7807465B2
(en)
*
|
2004-10-27 |
2010-10-05 |
Duke University |
Methods for identifying an individual at increased risk of developing coronary artery disease
|
|
US7833725B2
(en)
*
|
2005-01-06 |
2010-11-16 |
President And Fellows Of Harvard College |
Mass spectrometric methods and products
|
|
US20070092449A1
(en)
*
|
2005-04-05 |
2007-04-26 |
Rafael Vazquez-Martinez |
Methods for direct visualization of active synapses
|
|
US20070148661A1
(en)
*
|
2005-07-19 |
2007-06-28 |
Duke University |
LSAMP Gene Associated With Cardiovascular Disease
|
|
US7704695B2
(en)
*
|
2005-07-29 |
2010-04-27 |
Xenoport, Inc. |
Screening of compounds for BGT1 transporter activity
|
|
US7670782B2
(en)
*
|
2005-07-29 |
2010-03-02 |
Xenoport, Inc. |
Screening of compounds for CAT1 transporter activity
|
|
WO2007016159A2
(en)
*
|
2005-07-29 |
2007-02-08 |
Xenoport, Inc. |
Gat2 transporters expressed in blood brain barrier cells
|
|
US7704696B2
(en)
*
|
2005-07-29 |
2010-04-27 |
Xenoport, Inc. |
Screening of compounds for OCTN2 transporter activity
|
|
WO2007016161A2
(en)
*
|
2005-07-29 |
2007-02-08 |
Xenoport, Inc. |
Oct3 transporters expressed in blood brain barrier cells
|
|
CA2618508A1
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating alzheimer's disease
|
|
US20090226420A1
(en)
*
|
2005-11-10 |
2009-09-10 |
Elizabeth Hauser |
Methods of Determining the Risk of Developing Coronary Artery Disease
|
|
US8852585B2
(en)
|
2006-01-30 |
2014-10-07 |
Grifols Therapeutics Inc. |
Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
|
|
CA2641555A1
(en)
*
|
2006-02-06 |
2007-08-16 |
Elan Pharmaceuticals, Inc. |
Preferential inhibition of presenilin-1
|
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
|
US7851228B2
(en)
*
|
2006-03-31 |
2010-12-14 |
The Regents Of The University Of California |
Methods for screening agents that modulate presenilin activity and A-β production
|
|
WO2007124751A2
(en)
*
|
2006-05-01 |
2007-11-08 |
Aarhus Universitet |
An animal model and a method for producing an animal model
|
|
US7771741B2
(en)
*
|
2006-05-01 |
2010-08-10 |
Warsaw Orthopedic, Inc |
Demineralized bone matrix devices
|
|
DK2134846T3
(en)
*
|
2007-03-07 |
2018-11-26 |
Univ Aarhus |
Transgenic swine as a model for Alzheimer's disease
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9068006B2
(en)
|
2010-08-25 |
2015-06-30 |
President And Fellows Of Harvard College |
Glycated CD59 peptides, their preparation, and uses thereof
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US20140193341A1
(en)
*
|
2011-01-19 |
2014-07-10 |
Asa Abeliovich |
Human induced neuronal cells
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012178183A1
(en)
*
|
2011-06-24 |
2012-12-27 |
Board Of Regents, The University Of Texas System |
Human age-related neurodegenerative nematode model and methods
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
WO2013090186A1
(en)
*
|
2011-12-14 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleic acids, and acute care uses thereof
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
ES2530141B1
(es)
*
|
2013-08-26 |
2016-01-15 |
Juan Carlos GALLAR RUIZ |
Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad.
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
AU2016321298A1
(en)
|
2015-09-09 |
2018-03-29 |
The Trustees Of Columbia University In The City Of New York |
Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
EP3438128B1
(en)
*
|
2017-08-04 |
2020-05-20 |
Alzheimur 2012 S.L. |
Anti-presenilin antibody for use in the prevention and/or treatment of cancer
|
|
CA3100946A1
(en)
*
|
2018-05-22 |
2019-11-28 |
The Brigham And Women's Hospital, Inc. |
Gene therapy for alzheimer's disease
|
|
WO2020160156A2
(en)
|
2019-01-30 |
2020-08-06 |
Immutics, Inc. |
Anti-gal3 antibodies and uses thereof
|
|
JP7686573B6
(ja)
*
|
2019-05-24 |
2025-07-04 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
アルツハイマー病のための遺伝子治療
|
|
BR112022010373A2
(pt)
|
2019-11-29 |
2022-08-16 |
Paros Bio Inc |
Terapia genética para doenças neurodegenerativas
|
|
EP4157338A4
(en)
|
2020-05-26 |
2024-11-13 |
TrueBinding, Inc. |
METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
|
|
KR102584857B1
(ko)
*
|
2020-09-23 |
2023-10-06 |
재단법인대구경북과학기술원 |
알츠하이머 동물모델 및 이의 용도
|
|
KR20230009140A
(ko)
*
|
2021-07-08 |
2023-01-17 |
주식회사 엠케이바이오텍 |
Human mutant Presenilin-1 발현 인지장애 모델 개의 생산
|